Arecor Therapeutics Share Discussion Threads

[stupidboypike] 28/1/2022 09:37

Interview with Sarah Howell (CEO)
hxxps://youtu.be/sonkdkpC8LU

[alloa2003] 25/1/2022 21:22

Buyers nibbling at the stock - one to buy and tuck away.

[stupidboypike] 24/1/2022 09:08

Also a sale of the diabetes franchise definitely does not need a sale of the company. It could relatively easily be spun out as a separate entity. Indeed, as I understand it, that was always the business plan. Best regards SBP

[alloa2003] 23/1/2022 19:01

Why would there only be two possible bidders? I am sure there are other pharmas with deep pockets who have been looking to get into the insulin market for years? This company is not just about the insulin treatment either so I dont wholly agree with your arguements.

[mw8156] 23/1/2022 18:30

expect their ultra-fast insulin trials to succeed that ought to promote a bid from one or both of the 2 insulin majors to access the programme as they don't have the resource to market it themselves.
Risk is that the trial gets delayed because of the pandemic.
Only problem is there are only 2 possible purchasers who would be reluctant to overpay?

[stupidboypike] 23/1/2022 13:48

alioa,

You are spot on there. In fact given that Arecor have the technology to reduce or remove the need for cold chain for vaccines, an analyst did ask if they were working on any of the covid vaccines, which famously need a significant cold chain. The answer was "we can not comment for confidentiality reasons". It wouldn't surprise me at all to wake up one morning to a blockbuster RNS along those lines.

Best regards SBP

[alloa2003] 23/1/2022 12:37

Perfect summaries!

The golden nugget that others might miss is that due to the confidential nature of the work they do (and the fact big pharms dont like to admit they need help improving their treatments) a lot of the work they do will not be made public. The results will be, but not the names they are working with.

At some point this potential cashcow would make a great add-on for one of those larger groups that service the pharma sector.

[stupidboypike] 23/1/2022 11:47

jimbo, and to add to that, their "bread and butter" business of working on other companies drugs at no risk because of money up front, then royalties on success, is also looking very strong indeed. It is also my largest holding by a margin, I am significantly over any % recommended in one share, but don't lose any sleep about this at all. Over a 2 to 3 year horizon, I think this is about as good as it gets.

Best regards SBP

[jimbo123elf] 22/1/2022 06:03

The size of the market for Arecor's proprietary diabetes pipeline is estimated to be $6.4bn, their proprietary speciality hospital candidate $250m-1bn, AT282 $600m, AT307 $300m, AT220 $2bn+ and AT292 $1.1bn. I am very happy to support Arecor in the years to come and can't wait to see what further progress they make in the future. I have made it my largest holding.

[alloa2003] 20/1/2022 18:30

Totally agree - doing everything right. Shame about the spread which - even though it has tightened - doesnt help.

[stupidboypike] 20/1/2022 08:43

Great news this morning. We knew the trial was scheduled to start in 2022, but I didn't expect 20 days in. I love this company, massive upside, protected downside. Over a 2 year view I think this is a wonderful investment, and I have acted accordingly.

Best regards SBP

[alloa2003] 20/1/2022 07:53

It wouldnt take much buying to push this one higher.

[18bt] 20/1/2022 07:51

That and a steady as she goes trading announcement - with the snippet that another EU patent has been granted. More than happy to hold for long term gains.

[alloa2003] 20/1/2022 07:46

"Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it has commenced the US
Phase I clinical trial of Arecor's lead product, AT247, an ultra-rapid insulin to be delivered by continuous subcutaneous infusion via insulin pump over a period of three days."

Should hopefully get the company and its treatment line back in the news again.

[alloa2003] 14/1/2022 09:34

I am back into this one - it has so many different types of income streams. There is also a lot going on behind the scenes with partners not comfortable making public that they need "improvements" to their treatments and the way they are delivered. One to tuck away and forget about for a couple of years.

[mw8156] 27/12/2021 21:46

sbp

well-spotted, thanks- it's a good write-up and refers to other relationships with major pharma not in the public domain, (also an extra e in eli lilly as well as arecor!)

[stupidboypike] 27/12/2021 20:38

Lovely piece in the standard:-



Apart from mis-spelling Arecor in the headline!

[18bt] 21/12/2021 10:48

So the purpose of today's announcement (which wasn't immediately clear to me when I read it) is:
- the final formulation is actually going to be a little late, but
- clarifies that a milestone payment is due when it is transferred

Anyway it is broadly confirmation that progress is being made.

[18bt] 21/12/2021 10:45

A reminder of what was said in the prospectus about Hikma and AT282 (from different places so slightly repetitive in parts):

"Arecor is also applying the Arestat™ technology to develop a number of different ready-to-use (“RTU”) and ready-to-administer (“RTA”) medicines that have the potential to provide a safer, more convenient and immediate treatment options, with the aim of partnering these products to generate milestone and sales-based royalty payments. Two of these programmes have already been partnered with Hikma, validating the commercial interest in this product class. Owing to the Group’s strategy of reformulating existing therapeutic products, there is potential to develop these products under an expedited regulatory pathway, with the Directors estimating the potential commercial launch of one of the Hikma partnered products from 2023, with further products potentially launching between 2023 and 2025. The combined global market size of the seven specialty hospital products (including the two Hikma partnered products) currently under Arecor development is estimated to be approximately US$3.8 billion.

Of the four partnered programmes, two are part of the Group’s Specialty Hospital Care franchise and are partnered with Hikma. The Directors believe that one of the two programmes partnered with Hikma has the potential to launch from 2023, with the other programme expected to potentially launch between 2023 and 2025. Both licences with Hikma benefit the Group from potential near term associated development and commercialisation milestone payments and royalty revenue.

In January 2020, Arecor Limited announced that it had entered into an exclusive agreement to co-develop a new ready-to-use injectable medicine in the United States through Hikma’s affiliate, Hikma Pharmaceuticals USA, Inc. In October 2020, Arecor entered a second exclusive agreement with Hikma Pharmaceuticals USA, Inc. to co-develop a further ready-to-administer injectable medicine.

AT282 (partnership with Hikma)
In January 2020, Arecor and Hikma, a multinational generic pharmaceutical company, announced an exclusive agreement to co-develop a new, RTU injectable medicine in the United States through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc. As described in section 5.2, RTU medicines have the potential to provide safer, more convenient and immediate treatment option for patients and healthcare providers. This product is being developed using Arecor’s proprietary drug formulation technology platform Arestat™ and Hikma will seek approval for the product under the US Food and Drug Administration’;s 505(b)(2) regulatory pathway. It is the Director’s belief that no clinical trials will be required before regulatory submission, which the Directors estimate could be filed for approval from 2023.
Under the terms of the royalty-based agreement, Arecor has received an upfront payment and will receive further payments on the achievement of development, regulatory and commercial milestones. Hikma is responsible for the manufacture and commercialisation of the product. Arecor retains the right to develop and commercialise the product in certain markets outside the United States. The Group expects to transfer the final formulation of AT282 to Hikma in 2021. Hikma will generate all data required for regulatory submission and approval in its territories, including the United States. These studies will be fully funded by Hikma.

Further information on the clinical development pathway of AT282 is set out in section 7 of this Part I. Hikma will be responsible for the manufacture and commercialisation of the product.

Accelerated development: Specialty Hospital Products
Arecor is developing a number of specialty hospital products, including two under licencing partnership with Hikma (see Section 4.3.2 of Part I of this document). All of the products are re-formulations of an existing, approved medicine where the aim of the re-formulation is to develop RTU and RTA medicines that have the potential to provide a safer, more convenient and immediate treatment options.
For example, AT282 is a novel formulation of an already marketed product that is only available as a lyophilised powder that needs to be re-constituted before use. AT282 is being developed as a stable, liquid concentrate and so is referred to as a RTU product.
Arecor is responsible for optimising the AT282 novel formulation and demonstrating that it meets the required stability criteria. The final formulation will then be transferred to Hikma (partner company for AT282), which is expected to occur during 2021. Hikma will generate all data required for regulatory submission and approval in its territories, including the United States. These studies will be fully funded by Hikma.
As a reformulation of an existing product, Karios expects that AT282 and our other specialty hospital products will be approved under the abbreviated US Food and Drug Administration’;s 505(b)(2) regulatory pathway and in the EU under the Directive 2001/83/EC Hybrid pathway.

These pathways are abbreviated as evidence of safety and clinical efficacy has been generated for the original products, which may be relied upon in the regulatory application for marketing authorisation for Arecor’s specialty hospital products, meaning in many cases, further clinical studies may not be required. This in turn, may allow for a reduced development time and cost to marketing authorisation. At this time, it is assumed by the Directors that clinical studies will not be required for the products being developed in the Group specialty hospital products franchise.

Of the four partnered programmes, two are part of the Group’s Specialty Hospital Care franchise and are partnered with Hikma. The Directors believe that one of the two programmes partnered with Hikma has the potential to launch from 2023, with the other programme expected to potentially launch between 2023 and 2025. Both licences with Hikma benefit the Group from potential near term associated development and commercialisation milestone payments and royalty revenue.

Under the terms of the Hikma royalty-based agreements, Arecor has received an upfront payment and further payments are expected upon achievement of development, regulatory and commercial milestones. Hikma will be responsible for the manufacturing and commercialisation of the product. The Directors anticipate that the partnered programmes could be launched in the period from 2023 to 2025 with near term associated milestones and royalty revenue.

[18bt] 14/12/2021 09:29

That’s a great spot.. they must supply a lot of reagents to work with the sequencing machines. But it would be a great reference to have if successful.

[stupidboypike] 14/12/2021 08:36

Brilliant spot jimbo. I really love this aspect to Arecor, bread and butter business, where we can not lose, get paid to develop, nice upside if it works! A real comfort, if for any reason the blockbuster diabetes products fail to shine.

Best regards SBP

[jimbo123elf] 14/12/2021 07:35

It sounds like they are working with Illumnia. "Our partner's products are used for applications in life sciences, oncology, reproductive health, agriculture and other emerging segments, expanding our reach into new markets."

"Illumina's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments."

[18bt] 14/12/2021 07:20

Another strong affirmation of the platform this morning.

[jimbo123elf] 26/11/2021 13:02

A company with the capability to reformulate vaccines. No COVID risks here.

[stupidboypike] 23/11/2021 21:43

Nice piece from the CEO:-
hxxps://www.bgf.co.uk/stories-of-growth/sarah-howell-ceo-of-arecor/

Best regards

SBP